Immunomedics‘ IMMU-132, an antibody-drug conjugate for solid cancer therapy, has received Orphan Drug status from the Office of Orphan Products Development of the FDA for the treatment of small cell lung cancer (SCLC). In an early Phase I clinical study, IMMU-132 has produced partial responses in patients with small cell lung cancer, colorectal cancer, and triple negative breast cancer. IMMU-132 is currently in Phase II clinical development focusing on a few select types of solid cancers....